GLP-1受体激动剂与SGLT-2抑制剂对体重和血糖控制的有效性:一项目标试验的观察性模拟
本研究利用Clalit医疗记录观察性数据,模拟目标试验,比较三种GLP-1受体激动剂(利拉鲁肽、度拉糖肽、司美格鲁肽)与SGLT-2抑制剂在2型糖尿病合并肥胖患者中的体重和HbA1c变化。结果显示,利拉鲁肽和度拉糖肽在5年内降糖优于SGLT-2抑制剂且减重相似,司美格鲁肽短期减重和降糖均更优。
要点
- 利拉鲁肽和度拉糖肽5年减重与SGLT-2抑制剂相似(6.4–7.3 kg)。
- 司美格鲁肽18个月减重比SGLT-2抑制剂多2.6 kg(95%CI 1.2–4.0)。
- 三种GLP-1 RA在18个月HbA1c降幅均大于SGLT-2抑制剂,且优势维持。
核心结论
- 与SGLT-2抑制剂相比,利拉鲁肽和度拉糖肽在5年内提供更优的血糖控制且减重相似,司美格鲁肽短期减重和降糖均更优。
研究设计与样本
- 利用Clalit医疗记录观察性数据,模拟目标试验,比较三种GLP-1 RA与SGLT-2抑制剂在2型糖尿病合并肥胖患者中的效果。
- 纳入利拉鲁肽4296例、度拉糖肽11159例、司美格鲁肽5041例。
- 主要结局为随访期间体重和HbA1c的绝对变化(利拉鲁肽/度拉糖肽随访至5年,司美格鲁肽至3年)。
- 采用逆概率加权调整潜在混杂因素。
主要发现
- 5年时利拉鲁肽和度拉糖肽减重6.4–7.3 kg,与SGLT-2抑制剂相似。
- 18个月时司美格鲁肽减重比SGLT-2抑制剂多2.6 kg(95%CI 1.2–4.0)。
- 18个月时HbA1c降幅利拉鲁肽比SGLT-2抑制剂多0.4%(95%CI 0.3–0.5),度拉糖肽多0.7%(95%CI 0.6–0.8),司美格鲁肽多0.6%(95%CI 0.5–0.8)。
- HbA1c优势在整个随访期间维持。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ABSTRACT Aims Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT-2is) are both recommended as second-line treatments for individuals with Type 2 diabetes and obesity, but long-term head-to-head randomized trials in this population are lacking, necessitating a real-world evaluation of their relative benefits in weight loss and glycaemic control. Materials and Methods Using observational data from Clalit's medical records, separate target trials were emulated comparing three GLP-1 RAs (liraglutide, dulaglutide and semaglutide) with SGLT-2is in individuals with Type 2 diabetes and obesity. The main outcomes were absolute changes in body weight and HbA1c during follow-up (up to 5 years for liraglutide/dulaglutide and 3 years for semaglutide). We used inverse-probability weighting to adjust for potential confounders. Results We identified 4296, 11 159 and 5041 eligible individuals initiating liraglutide, dulaglutide and semaglutide, respectively. Long-term weight loss was similar (6.4–7.3 kg at 5 years) for liraglutide and dulaglutide compared with SGLT-2is; weight loss for semaglutide was 2.6 kg (95% CI: 1.2–4.0) greater than for SGLT-2is at 18 months. At 18 months, HbA1c reductions were 0.4% (95% CI: 0.3–0.5), 0.7% (95% CI: 0.6–0.8) and 0.6% (95% CI: 0.5–0.8) greater for liraglutide, dulaglutide and semaglutide than SGLT-2is, respectively; this advantage was maintained throughout follow-up. Conclusions We estimated that, compared with SGLT-2is, liraglutide and dulaglutide provided superior glycaemic control and similar weight reduction over 5 years, and that semaglutide produced greater short-term reductions in both outcomes. Our analyses benchmark the results of short-term randomized trials and extend the evidence to longer periods.
引用
- Diabetes, Obesity and Metabolism:Effectiveness of GLP‐1 RAs and SGLT‐2is for Weight Loss and Glycaemic Control: An Observational Emulation of a Target Trial
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。